News & Updates
Filter by Specialty:

Real-world data support FTD/TPI plus bevacizumab for mCRC
03 Mar 2025
byAudrey Abella
A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.
Real-world data support FTD/TPI plus bevacizumab for mCRC
03 Mar 2025
Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients
03 Mar 2025
byChristina Lau
Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).